株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

潰瘍性大腸炎:パイプライン製品の分析

Ulcerative Colitis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 264709
出版日 ページ情報 英文 421 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
潰瘍性大腸炎:パイプライン製品の分析 Ulcerative Colitis - Pipeline Review, H2 2016
出版日: 2016年10月29日 ページ情報: 英文 421 Pages
概要

潰瘍性大腸炎 (UC) は、主に大腸に発生する慢性疾患で、炎症性腸疾患の一種です。腸における潰瘍が特徴で、喫煙、遺伝、肝疾患、大腸がん、うつ、重度脱水などの要因があります。一般的な症状は直腸出血、腹部痛、下痢などであり、手術、アミノサリチル酸薬 (ASA製薬) による薬剤治療、免疫調節療法やコルチコステロイドによる治療があります。

当レポートでは、潰瘍性大腸炎に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

潰瘍性大腸炎の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

潰瘍性大腸炎:企業で開発中の治療薬

潰瘍性大腸炎:大学/機関で研究中の治療薬

潰瘍性大腸炎:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

潰瘍性大腸炎:企業で開発中の製品

潰瘍性大腸炎:大学/機関で研究中の製品

潰瘍性大腸炎の治療薬開発に従事している企業

  • 4D Pharma Plc
  • AbbVie Inc.
  • Advinus Therapeutics Ltd.
  • 味の素 Pharmaceuticals Co., Ltd.
  • Am-Pharma B.V.
  • Amgen Inc.
  • Arena Pharmaceuticals, Inc.
  • Atlantic Healthcare Plc
  • Avaxia Biologics, Inc.
  • BioAtla, LLC
  • Bionovis SA
  • Celgene Corporation
  • Cellceutix Corporation
  • ChemoCentryx, Inc.
  • ChironWells GmbH
  • Chong Kun Dang Pharmaceutical Corp.
  • Coherus BioSciences, Inc.
  • Cosmo Pharmaceuticals S.p.A
  • Dr. Falk Pharma GmbH
  • Effimune S.A.
  • Eli Lilly and Company
  • Enceladus Pharmaceuticals BV
  • enGene, Inc
  • Enterome Bioscience SA
  • Epirus Biopharmaceuticals, Inc.
  • Flexion Therapeutics, Inc.
  • Genentech, Inc.
  • Genor BioPharma Co., Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • GW Pharmaceuticals Plc
  • iCo Therapeutics Inc.
  • Idera Pharmaceuticals, Inc.
  • InDex Pharmaceuticals AB
  • Innovate Biopharmaceuticals, Inc.
  • INOXIA Lifesciences GmbH
  • Intas Pharmaceuticals Ltd.
  • Invion Limited
  • Johnson & Johnson
  • 科研製薬
  • Kymab Limited
  • 協和発酵キリン
  • LIPID THERAPEUTICS GmbH
  • Mabion SA
  • Medestea Research & Production S.p.A.
  • 田辺三菱製薬
  • Momenta Pharmaceuticals, Inc.
  • Morphotek, Inc.
  • Mycenax Biotech Inc.
  • Oncobiologics, Inc.
  • Pfizer Inc.
  • Pluristem Therapeutics Inc.
  • ProtAb Ltd
  • Protagonist Therapeutics Inc.
  • Qu Biologics Inc.
  • Re-Pharm Limited
  • Rebiotix Inc.
  • Sandoz International GmbH
  • Seres Therapeutics, Inc.
  • Sigmoid Pharma Limited
  • Stelic Institute & Co., Inc.
  • sterna biologicals Gmbh & Co KG
  • Synergy Pharmaceuticals, Inc.
  • 武田薬品工業
  • Therapeutic Proteins International, LLC
  • Therapix Biosciences Ltd
  • Theravance Biopharma, Inc.
  • Tillotts Pharma AG
  • Trino Therapeutics Limited
  • Ventria Bioscience

潰瘍性大腸炎:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

潰瘍性大腸炎:最近のパイプライン動向

潰瘍性大腸炎:休止中のプロジェクト

潰瘍性大腸炎:開発が中止された製品

潰瘍性大腸炎:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8598IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H2 2016, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.

Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 14, 28, 20, 1, 1, 45, 12 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 1 molecules, respectively for Ulcerative Colitis.

Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Ulcerative Colitis Overview
  • Therapeutics Development
  • Ulcerative Colitis - Therapeutics under Development by Companies
  • Ulcerative Colitis - Therapeutics under Investigation by Universities/Institutes
  • Ulcerative Colitis - Pipeline Products Glance
  • Ulcerative Colitis - Products under Development by Companies
  • Ulcerative Colitis - Products under Investigation by Universities/Institutes
  • Ulcerative Colitis - Companies Involved in Therapeutics Development
  • Ulcerative Colitis - Therapeutics Assessment
  • Drug Profiles
  • Ulcerative Colitis - Dormant Projects
  • Ulcerative Colitis - Discontinued Products
  • Ulcerative Colitis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Ulcerative Colitis, H2 2016
  • Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Ulcerative Colitis - Pipeline by 4D Pharma Plc, H2 2016
  • Ulcerative Colitis - Pipeline by AbbVie Inc, H2 2016
  • Ulcerative Colitis - Pipeline by Abivax S.A., H2 2016
  • Ulcerative Colitis - Pipeline by Advinus Therapeutics Ltd, H2 2016
  • Ulcerative Colitis - Pipeline by Aerpio Therapeutics, Inc., H2 2016
  • Ulcerative Colitis - Pipeline by Am-Pharma B.V., H2 2016
  • Ulcerative Colitis - Pipeline by Amgen Inc., H2 2016
  • Ulcerative Colitis - Pipeline by Aptevo Therapeutics Inc, H2 2016
  • Ulcerative Colitis - Pipeline by Arena Pharmaceuticals, Inc., H2 2016
  • Ulcerative Colitis - Pipeline by Atlantic Healthcare Plc, H2 2016
  • Ulcerative Colitis - Pipeline by Bionovis SA, H2 2016
  • Ulcerative Colitis - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Ulcerative Colitis - Pipeline by Celgene Corporation, H2 2016
  • Ulcerative Colitis - Pipeline by Cellceutix Corporation, H2 2016
  • Ulcerative Colitis - Pipeline by ChemoCentryx, Inc., H2 2016
  • Ulcerative Colitis - Pipeline by ChironWells GmbH, H2 2016
  • Ulcerative Colitis - Pipeline by Coherus BioSciences, Inc., H2 2016
  • Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals NV, H2 2016
  • Ulcerative Colitis - Pipeline by Dr. Falk Pharma GmbH, H2 2016
  • Ulcerative Colitis - Pipeline by EA Pharma Co Ltd, H2 2016
  • Ulcerative Colitis - Pipeline by Eli Lilly and Company, H2 2016
  • Ulcerative Colitis - Pipeline by Enceladus Pharmaceuticals BV, H2 2016
  • Ulcerative Colitis - Pipeline by enGene, Inc, H2 2016
  • Ulcerative Colitis - Pipeline by Enterome Bioscience SA, H2 2016
  • Ulcerative Colitis - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016
  • Ulcerative Colitis - Pipeline by Flexion Therapeutics, Inc., H2 2016
  • Ulcerative Colitis - Pipeline by Galapagos NV, H2 2016
  • Ulcerative Colitis - Pipeline by Genentech, Inc., H2 2016
  • Ulcerative Colitis - Pipeline by Genor BioPharma Co Ltd, H2 2016
  • Ulcerative Colitis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Ulcerative Colitis - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Ulcerative Colitis - Pipeline by iCo Therapeutics Inc., H2 2016
  • Ulcerative Colitis - Pipeline by Idera Pharmaceuticals, Inc., H2 2016
  • Ulcerative Colitis - Pipeline by InDex Pharmaceuticals AB, H2 2016
  • Ulcerative Colitis - Pipeline by Innovate Biopharmaceuticals, Inc., H2 2016
  • Ulcerative Colitis - Pipeline by INOXIA Lifesciences GmbH, H2 2016
  • Ulcerative Colitis - Pipeline by Intas Pharmaceuticals Ltd., H2 2016
  • Ulcerative Colitis - Pipeline by Johnson & Johnson, H2 2016
  • Ulcerative Colitis - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2016
  • Ulcerative Colitis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016
  • Ulcerative Colitis - Pipeline by LIPID THERAPEUTICS GmbH, H2 2016
  • Ulcerative Colitis - Pipeline by Lycera Corp., H2 2016
  • Ulcerative Colitis - Pipeline by Medestea Research & Production S.p.A., H2 2016
  • Ulcerative Colitis - Pipeline by Merck & Co., Inc., H2 2016
  • Ulcerative Colitis - Pipeline by Miyarisan Pharmaceutical Company, Ltd, H2 2016
  • Ulcerative Colitis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016
  • Ulcerative Colitis - Pipeline by Morphotek, Inc., H2 2016
  • Ulcerative Colitis - Pipeline by Mycenax Biotech Inc., H2 2016
  • Ulcerative Colitis - Pipeline by NeuClone Pty Ltd, H2 2016
  • Ulcerative Colitis - Pipeline by Oncobiologics, Inc., H2 2016
  • Ulcerative Colitis - Pipeline by OSE Immunotherapeutics, H2 2016
  • Ulcerative Colitis - Pipeline by Pfizer Inc., H2 2016
  • Ulcerative Colitis - Pipeline by Pluristem Therapeutics Inc., H2 2016
  • Ulcerative Colitis - Pipeline by ProtAb Ltd, H2 2016
  • Ulcerative Colitis - Pipeline by Protagonist Therapeutics Inc., H2 2016
  • Ulcerative Colitis - Pipeline by Protalix BioTherapeutics, Inc., H2 2016
  • Ulcerative Colitis - Pipeline by Qu Biologics Inc., H2 2016
  • Ulcerative Colitis - Pipeline by Re-Pharm Limited, H2 2016
  • Ulcerative Colitis - Pipeline by Rebiotix Inc., H2 2016
  • Ulcerative Colitis - Pipeline by Sandoz International GmbH, H2 2016
  • Ulcerative Colitis - Pipeline by Seres Therapeutics, Inc., H2 2016
  • Ulcerative Colitis - Pipeline by Shire Plc, H2 2016
  • Ulcerative Colitis - Pipeline by Sigmoid Pharma Limited, H2 2016
  • Ulcerative Colitis - Pipeline by Stelic Institute & Co., Inc., H2 2016
  • Ulcerative Colitis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2016
  • Ulcerative Colitis - Pipeline by Synergy Pharmaceuticals, Inc., H2 2016
  • Ulcerative Colitis - Pipeline by Synlogic Inc, H2 2016
  • Ulcerative Colitis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Ulcerative Colitis - Pipeline by Therapeutic Proteins International, LLC, H2 2016
  • Ulcerative Colitis - Pipeline by Therapix Biosciences Ltd., H2 2016
  • Ulcerative Colitis - Pipeline by Theravance Biopharma, Inc., H2 2016
  • Ulcerative Colitis - Pipeline by Tillotts Pharma AG, H2 2016
  • Ulcerative Colitis - Pipeline by TopiVert Ltd, H2 2016
  • Ulcerative Colitis - Pipeline by Trino Therapeutics Limited, H2 2016
  • Ulcerative Colitis - Pipeline by UCB S.A., H2 2016
  • Ulcerative Colitis - Pipeline by Ventria Bioscience, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Ulcerative Colitis - Dormant Projects, H2 2016
  • Ulcerative Colitis - Dormant Projects (Contd..1), H2 2016
  • Ulcerative Colitis - Dormant Projects (Contd..2), H2 2016
  • Ulcerative Colitis - Dormant Projects (Contd..3), H2 2016
  • Ulcerative Colitis - Dormant Projects (Contd..4), H2 2016
  • Ulcerative Colitis - Dormant Projects (Contd..5), H2 2016
  • Ulcerative Colitis - Dormant Projects (Contd..6), H2 2016
  • Ulcerative Colitis - Dormant Projects (Contd..7), H2 2016
  • Ulcerative Colitis - Dormant Projects (Contd..8), H2 2016
  • Ulcerative Colitis - Dormant Projects (Contd..9), H2 2016
  • Ulcerative Colitis - Discontinued Products, H2 2016
  • Ulcerative Colitis - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Ulcerative Colitis, H2 2016
  • Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top